Part of Lumito's development team visited the development partner TTP's (The Technology Partnership) research and development campus, outside Cambridge in the UK, this week to discuss and plan the completion of Lumito's scanner, aimed for research laboratories, which will be launched during the later part of next year.
"We appreciate the opportunity to visit the TTP on site. It was most valuable to meet and discuss to agree on the common plan towards the launch objective next year. Both teams possess great expertise and experience and when we combine these strengths, progress and results happen", says Lumito's CEO Mattias Lundin.
For further information, please contact:
Lumito's CEO, Mattias Lundin
E-mail: ml@lumito.se
phone: +46 76-868 45 09
Also, visit our website.
Lumito specializes in medical technology for digital pathology. Through its proprietary and patented technology, Lumito aims to provide healthcare providers with a powerful tool to meet the demands for fast and safe tissue diagnostics in personalized healthcare. The technology enables higher contrast images where unimportant background information is sorted out, making it easier for pathologists to find cancer indications. The technology, based on Up Converting Nano Particles (UCNP), has the potential to significantly improve the diagnosis of tissue samples through higher quality analyses and shorter analysis times. The method has several potential applications, but Lumito has chosen to focus primarily on digital pathology. The company is a spin-off from a research group at Lund University's Department of Atomic Physics and Laser Centre. www.lumito.se.
The share is traded on NGM Nordic SME, under the name LUMITO and Mentor is Mangold Fondkommission, phone: +46 (8) 5030 1550 and email, ca@mangold.se.
